Companies / VRTX vs ABBV
VRTX vs ABBV: Vertex Pharmaceuticals and AbbVie
Vertex Pharmaceuticals (VRTX) reported $12.0B in revenue against a 32.9% net margin, while AbbVie (ABBV) reported $61.2B at a 6.9% net margin, most recently.
| Metric | VRTX | ABBV |
|---|---|---|
| Revenue | $12.0B | $61.2B |
| Net Income | $4.0B | $4.2B |
| Gross Margin | 86.2% | 70.2% |
| Operating Margin | 34.8% | 24.6% |
| EPS (Diluted) | $15.32 | $2.36 |
| Free Cash Flow | $3.2B | $17.8B |
| Total Debt | — | $67.0B |
| P/E Ratio | 29.6× | 96.8× |
| P/B Ratio | 6.2× | n/m |
| Stock Price | $542.69 | $288.14 |
Free: last 5 years
| Fiscal year | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VRTX Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B |
| ABBV Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B |